No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial

Jonathan Z. Li*, Paul E. Sax, Vincent C. Marconi, Jesse Fajnzylber, Baiba Berzins, Amesika N. Nyaku, Carl J. Fichtenbaum, Timothy Wilkin, Constance A. Benson, Susan L. Koletar, Ramon Lorenzo-Redondo, Babafemi O. Taiwo

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.

Original languageEnglish (US)
Article number56
JournalOpen Forum Infectious Diseases
Volume6
Issue number3
DOIs
StatePublished - Mar 2019

Keywords

  • ART simplification
  • ART switch
  • Dolutegravir
  • Lamivudine
  • Residual viremia

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial'. Together they form a unique fingerprint.

  • Cite this

    Li, J. Z., Sax, P. E., Marconi, V. C., Fajnzylber, J., Berzins, B., Nyaku, A. N., Fichtenbaum, C. J., Wilkin, T., Benson, C. A., Koletar, S. L., Lorenzo-Redondo, R., & Taiwo, B. O. (2019). No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. Open Forum Infectious Diseases, 6(3), [56]. https://doi.org/10.1093/ofid/ofz056